Profile
ACXP NVO VRTX REGN SGEN ARGX
Company Name Acurx Pharmaceuticals, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $23.48M $456.40B $116.20B $80.34B $43.15B $35.73B
Employees 0.00K 71.88K 5.40K 14.17K 3.26K 1.15K
CEO Mr. David P. Luci CPA, Esq., J.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
ACXP NVO VRTX REGN SGEN ARGX
Quant Rating Score 2 3 3 4 3 1
Quant Rating Sell Neutral Neutral Buy Neutral Strong Sell
Trading
ACXP NVO VRTX REGN SGEN ARGX
Last Close $1.39 $105.27 $451.23 $743.35 $228.74 $591.82
High 52 $4.81 $146.91 $516.74 $1201.76 $228.74 $602.47
Low 52 $1.37 $101.74 $392.81 $743.35 $228.74 $356.01
Price vs. 52 Week High -71.1 % -28.34 % -12.68 % -38.14 % 0 % -1.77 %
Price vs. 52 Week Low 1.46 % 3.47 % 14.87 % 0 % 0 % 66.24 %
Total Return
ACXP NVO VRTX REGN SGEN ARGX
1 Month Return -29.08 % -10.28 % -5.62 % -23.25 % 0 % 5.6 %
3 Month Return -40.34 % -22 % -7.18 % -37.29 % 0 % 12.62 %
6 Month Return -50.18 % -22.11 % 2.09 % -25.21 % 0 % 65.93 %
9 Month Return -52.88 % -12.95 % 7.53 % -21.99 % 0 % 47.97 %
YTD Return -63.71 % 1.76 % 10.9 % -15.36 % 0 % 55.57 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACXP NVO VRTX REGN SGEN ARGX
Dividend Yield Percentage (TTM) - 1.42 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.24 % -2.62 % 4.88 % -2.27 % -2.22 %
Dividend Per Share (TTM) - 0.21 % - - - -
Payout Ratio (TTM) - 46.6 % - - - -
Growth
ACXP NVO VRTX REGN SGEN ARGX
Asset Growth -17.78 % 30.35 % 25.23 % 13.23 % -1.21 % 44.93 %
Gross Profit Growth - 32.32 % 9.25 % 6.49 % 22.93 % 190.7 %
Revenue Growth - 31.26 % 10.17 % 7.76 % 24.65 % 198.56 %
Revenue 3 Year - 90.51 % 59.87 % 55.67 % 91.84 % 2074.24 %
Revenue 5 Year - 124.2 % 218.58 % 110.3 % 215.48 % 3040.37 %
Revenue 10 Year - 66.11 % 608.27 % 549.62 % 494.04 % 9013.37 %
EBIT Growth -20.54 % 37.11 % -12.94 % -14.6 % 10.13 % 40.94 %
Net Income Growth -20.56 % 50.71 % 8.96 % -8.87 % 9.51 % 58.42 %
Net Income 3 Yeari Growth Per Share -148.01 % 106.79 % 34.59 % 13.48 % -764.83 % 63.97 %
Net Income 5 Yeari Growth Per Share -92.34 % 133.86 % 70.33 % 74.02 % -276.93 % -143.56 %
Net Income 10 Yeari Growth Per Share -92.34 % 98.61 % 809.6 % 871.12 % -624.16 % -857.4 %
Operating Income Growth -20.54 % 37.11 % -12.94 % -14.6 % 10.13 % 40.94 %
Operating Cash Flow Growth (CFG) -29.95 % 38.06 % -14.35 % -8.39 % 9.07 % 51.28 %
Operating 3 Year CFG -128.85 % 118.29 % 9.63 % 76.95 % -148.34 % 21.62 %
Operating 5 Year CFG -92.46 % 163.51 % 174.78 % 125.17 % -195.86 % -329.48 %
Operating 10 Year CFG -92.46 % 150.92 % 6084.35 % 713.56 % -2622.09 % -1280.79 %
EPS Growth -2.68 % 52.28 % 8.33 % -8.54 % 10.81 % 60.46 %
EPS Diluted Growth -2.68 % 52.37 % 8.35 % -9.03 % 10.81 % 60.46 %
Book Value Per Share -45.54 % 29 % 25.58 % 15.03 % -9.83 % 38.53 %
Share Holder 3 Year Equity Growth Per Share 35.18 % 75.22 % 104.06 % 137.56 % 33.92 % 93.95 %
Share Holder 5 Year Equity Growth Per Share 345.46 % 121.9 % 291.14 % 219.1 % 220.81 % 318.67 %
Share Holder 10 Year Equity Growth Per Share 345.46 % 49.62 % 1030.79 % 1286.9 % 691.19 % 3655.65 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - 80.03 % - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth - 4.74 % 44.1 % 0.06 % -23.28 % 60.95 %
Free Cash Flow Growth -29.95 % 9.17 % -16.47 % -17.11 % 3.67 % 51.98 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
ACXP NVO VRTX REGN SGEN ARGX
Gross Profit Margin TTM - 84.66 % 86.1 % 83.54 % 72.37 % 86.82 %
Return on Assets TTM -47.39 % 23.83 % -2.16 % 12.43 % -11.76 % -2.13 %
Return on Equity TTM -67679.28 % 86.4 % -2.88 % 16.85 % -16.53 % -2.75 %
Return on Capital Employed TTM -0.51 % 62.9 % -1.72 % 11.85 % -16.87 % -8.98 %
Net Income Per EBT TTM 17250.11 % 79.43 % -184.82 % 93.66 % 100.55 % 167.72 %
EBT Per Ebit TTM 120.73 % 100.27 % -82.68 % 124.1 % 94.01 % 15.76 %
EBIT Per Revenue TTM - 43.96 % -2.96 % 28.92 % -36.09 % -17.08 %
Cash Flow To Debt Ratio TTM - 207.5 % - 214.08 % -185.98 % -
Receivables Turnover TTM - 3.4 6.06 2.27 1.98 3.45
Payables Turnover TTM - 1.72 3.73 4.58 1.54 1.06
Inventory Turnover TTM - 1.09 1.37 0.76 0.65 0.91
Fixed Asset Turnover TTM - 225.8 % 422.11 % 311.93 % 256.83 % 6116.64 %
Asset Turnover TTM - 68.08 % 47.71 % 36.98 % 34.46 % 47.09 %
Operating Cash Flow Per Share TTM -497.28 26.54 -3.27 39.29 -1.12 -2.42
Free Cash Flow Per Share TTM -497.28 15.05 -4.51 31.25 -1.62 -3.52
Cash Per Share TTM 35216.02 % 1681.3 % 2528.88 % 9062.44 % 657.5 % 5163.05 %
Operating Cash Flow Sales Ratio TTM - 43.69 % -7.94 % 30.67 % -16.85 % -6.44 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 56.7 % 138.12 % 79.52 % 144.14 % 145.12 %
Cash Flow Coverage Ratios TTM - 207.5 % - 214.08 % -185.98 % -
Price To Free Cash Flows Ratio TTM - 48.27 -99.85 23.78 -141.85 -169.15
Price To Operating Cash Flows Ratio TTM - 28.12 -138.16 18.92 -203.89 -244.33
Price Cash Flow Ratio TTM - 28.12 -138.16 18.92 -203.89 -244.33
Income Statement (TTM)
ACXP NVO VRTX REGN SGEN ARGX
Revenue $0B $232.26B $9.87B $13.12B $1.96B $1.23B
Gross Profit $0B $196.5B $8.61B $11.3B $1.55B $1.11B
Gross Profit Ratio 0% 84.6% 87.21% 86.16% 79.1% 90.39%
EBITDA $0B $114.63B $4.61B $4.65B $-0.62B $-0.22B
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.3B
EPS Diluted -1.15 18.62 13.89 34.77 -3.3 -5.16
Balance Sheet (MRQ)
ACXP NVO VRTX REGN SGEN ARGX
Long Term Debt $0B $20.53B $1.45B $2.7B $0.04B $0.02B
Total Liabilities $0B $207.93B $5.15B $7.11B $0.87B $0.44B
Total Equity $0B $106.56B $17.58B $25.97B $2.8B $4.1B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $1.18B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $0.02B
Total Assets $0.01B $314.49B $22.73B $33.08B $3.67B $4.54B
Cash Flow Statement (TTM)
ACXP NVO VRTX REGN SGEN ARGX
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.43B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $-0.08B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $108.91B $3.54B $4.59B $-0.45B $-0.42B
Capital Expenditure $0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.04B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.2742
ABCL AbCellera Biologics Inc. 2.715
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.815
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.3051
ABSI Absci Corporation 2.55
ABUS Arbutus Biopharma Corporation 3.475
ABVC ABVC BioPharma, Inc. 0.5443
ABVX Abivax SA American Depositary Shares 8.66
ACAD ACADIA Pharmaceuticals Inc. 16.205
ACER Acer Therapeutics Inc. 0.9
ACET Adicet Bio, Inc. 0.921
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.07
ACHV Achieve Life Sciences, Inc. 4.33
ACIU AC Immune SA 3.29
ACLX Arcellx, Inc. 87.19
ACRV Acrivon Therapeutics, Inc. Common Stock 6.45
ACST Acasti Pharma Inc. 3.37
ETFs With Exposure to ACXP
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 295.135
VXF Vanguard Extended Market Index Fund 0 200.05
IWC iShares Micro-Cap ETF 0.0044 132.68
DFAC Dimensional U.S. Core Equity 2 ETF 0.000002 35.82
VTSAX Vanguard Total Stock Market Index Fund 0 142.62
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 149.17
VITSX Vanguard Total Stock Market Index Fund 0 142.64
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 149.17
VEMPX Vanguard Extended Market Index InstlPlus 0 368.12
VSMPX Vanguard Total Stock Mkt Idx Instl Pls 0 267.57
Unlock